Expanded-access for the Use of Setmelanotide in a Single Patient With Partial Lipodystrophy (LD) Associated With Leptin Deficiency and Multiple Autoimmune Diseases
Latest Information Update: 06 Jan 2022
At a glance
- Drugs Setmelanotide (Primary)
- Indications Hypertriglyceridaemia; Lipodystrophy; Obesity
- Focus Adverse reactions; Expanded access; Therapeutic Use
- Sponsors Rhythm
Most Recent Events
- 29 Aug 2017 New trial record